Business context and reporting period
The supplied filing is ChromaDex Corporation’s Form 10-K for the 52-week fiscal year ended January 2, 2016, with quarterly information for the three months ended that date. The request metadata names Niagen Bioscience, Inc.; that name does not match the registrant identified in the filing. ChromaDex operated ingredients, core standards and contract services, and scientific and regulatory consulting businesses. NIAGEN (nicotinamide riboside, or NR) was its leading proprietary ingredient.
Financial performance and condition
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Net sales | $22.01 million | $15.31 million |
| Gross profit | $8.48 million; 38.5% margin | $5.33 million; 34.8% margin |
| Operating loss | $2.15 million | $5.23 million |
| Net loss | $2.77 million; $0.03 per share | $5.39 million; $0.05 per share |
| Cash used in operations | $2.11 million | $2.58 million |
| Cash at year-end | $5.55 million | $3.96 million |
- Sales rose 44%. Ingredients revenue increased 83% to $12.54 million, chiefly on NIAGEN and other ingredient sales; core standards and contract services grew 12% to $8.42 million, and consulting grew 9% to $1.05 million.
- Gross margin improved as ingredient suppliers reduced prices with higher purchase volumes. Core standards gross profit declined 12%, partly due to write-downs of slow-moving and obsolete reference-standard inventory.
- Research and development expense rose 74% to $892,000, focused on the ingredients business. General and administrative expense fell 6% to $7.42 million, partly because share-based compensation declined to about $1.98 million from $2.92 million.
- Interest expense rose to $616,000 from $159,000, largely reflecting the Hercules term loan and its second draw.
- Inventory increased to $8.17 million from $3.73 million, including $7.20 million of bulk ingredients. Accounts payable rose to $6.22 million from $3.45 million; management attributed much of both increases to ingredient inventory purchasing and payment timing.
- Investing activities used $648,000, versus $1.59 million provided in FY 2014. Financing activities provided $4.34 million, including the $2.5 million second loan draw and $1.97 million net proceeds from a stock offering. Year-end total assets were $18.75 million and stockholders’ equity was $5.27 million.
- At year-end, current assets were $16.55 million and current liabilities $9.59 million. The filing’s stated $4.40 million “working capital” is a company-defined measure of receivables plus inventory less accounts payable, not the conventional current-assets-minus-current-liabilities calculation.
For the fourth quarter, net sales were $4.36 million, gross profit $1.60 million, operating loss $1.24 million and net loss $1.43 million. The comparable prior-year quarter had sales of $4.24 million and net loss of $1.23 million.
Material changes versus the prior comparable period
- Growth increasingly depended on ingredients: the segment contributed $12.54 million of FY 2015 sales, versus $6.86 million in FY 2014. NIAGEN represented approximately 68% of ingredient-segment sales, compared with 54% in 2014.
- Despite higher sales and improved gross margin, the company remained loss-making. Operating loss narrowed substantially, while net loss also improved; increased interest expense partially offset operating improvement.
- Inventory growth exceeded sales growth and drove a significant operating cash use. Management said bulk purchases secured favorable pricing and described changes to reference-standard purchasing intended to improve turnover.
- The company drew the remaining $2.5 million available under its Hercules loan in June 2015, bringing principal outstanding to $5.0 million. The interest-only period was extended through March 31, 2016, after which scheduled principal and interest payments were to begin.
Outlook, risks, contingencies and unusual items
- Management expected cash, cash equivalents and cash generated from operations to fund its projected operating plan through at least March 18, 2017, but said additional financing might be needed and was not committed. The filing gives no numerical revenue or earnings guidance.
- Management planned to increase R&D for proprietary ingredients, subject to available financial resources, and anticipated further clinical trials for NR, pterostilbene and pipeline products. NR received FDA New Dietary Ingredient recognition in 2015 and an independent panel’s GRAS determination; these statements do not establish approval of health claims or drug uses.
- Key risks include continued losses and financing needs; variable-rate debt and restrictive loan covenants; dependence on customer acceptance, regulatory developments and intellectual-property protection; supplier and manufacturing concentration; product liability; and inventory obsolescence. One ingredients customer accounted for 11% of total sales in 2015.
- The $5.0 million Hercules loan bears a variable rate, reported as 9.60% at year-end, and is secured by substantially all company assets except intellectual property. Contractual obligations totaled $11.16 million, including $5.19 million of loan payments, $4.23 million of purchase obligations, and capital and operating leases. The loan also carries an end-of-term charge.
- Subsequent events included a $500,000 registered direct offering in March 2016, extensions of the Boulder research-facility and Rockville office leases, and executive salary increases. The filing also disclosed a NIAGEN supply and resale arrangement with Healthspan Research, whose manager and 91% owner was a ChromaDex director; as of year-end, no product had shipped and no equity interest had been issued.
- The company discontinued commercialization efforts for one licensed patent and wrote off its approximately $78,000 carrying value. Management reported no legal proceedings expected to have a material adverse effect. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for ChromaDex Corporation, not Niagen Bioscience, Inc.
- Track whether NIAGEN revenue growth, customer diversification and the disclosed P&G joint-development milestones convert into sustained sales, margins and cash generation.
- Assess inventory quality, turnover, purchase commitments and supplier concentration, particularly given the year-over-year inventory increase and the company’s reliance on bulk ingredient purchases.
- Review post-March 2016 cash, operating burn, debt amortization, covenant compliance and financing needs against management’s stated liquidity runway.
- Review the terms, performance conditions and related-party safeguards of the Healthspan arrangement, as well as dilution from outstanding options and warrants and subsequent stock offerings.